About 3.7 billion people -- 67% of us -- carry the herpes simplex virus-1 in our nerves cells where it lies quiescent until triggered by stress or injury. When activated, its symptoms are usually mild, limited to cold sores or ulcers in our mouth.

很少,病毒可以旅行神经元to the brain, where it can cause a life-threatening infection. This accounts for 5 to 15% of all cases of infectious encephalitis in children and adults. Doctors typically prescribe an anti-viral called acyclovir. But even so, the patients often suffer from long-lasting and debilitating memory loss, seizures and other cognitive disorders.

In such cases, doctors could trial an anti-viral in combination with a drug that curbs inflammation to see whether it offers a better prognosis, suggests a new "Nature Microbiology" study by scientists at the Max Delbrück Centre for Molecular Medicine in the Helmholtz Association in Berlin. The scientists made this discovery using a three-dimensional model of the brain grown from human stem cells. The use of such models, called organoids, is at the frontier of clinical medicine.

"These proto-brains contain hundreds of thousands of neurons that can communicate with each other in a synchronized manner. Important experiments can be conducted with them that were impossible a few years ago," says Professor Nikolaus Rajewsky, Scientific Director of the Berlin Institute for Medical Systems Biology at the Max Delbrück Center (MDC-BIMSB) and senior author of the study.

Dr. Agnieszka Rybak-Wolf, who heads the Organoid Technology Platform at the Max Delbrück Center and is one of the first authors, created the organoids, which were white, 0.5 cm blobs. "Brain organoids look a bit like small clouds of tissue," she says.

Closer to reality for herpes

Without organoids, analyzing HSV-1-induced encephalitis is challenging. The virus infects only people and getting these brain samples is impractical. Scientists defaulted to studying the disease in cultured nerve cells or in mice, which are not natural carriers of the virus.

"This model is now much closer to reality for the herpes virus than what has been used previously," says Dr. Emanuel Wyler, a virus expert who studies the molecular mechanisms of HSV-1 infections at the Landthaler lab and one of the first authors.

The scientists infected the organoids with the HSV-1 virus and visualized the neuroepithelial and neuronal cells as the virus rampaged and the mini-brain disintegrated. "We had these beautiful microscopy images that are so clear and you can see what is actually going on," Wyler says.

他们下一个进行了单细胞分析identify all the molecular pathways active during infection. "We used an unbiased approach to find all the pathways and genes that matter," says Dr. Ivano Legnini, a systems biologist previously at the Rajewsky lab, and one of the first authors. "We bring systems biology to the table."

They noticed that a signaling pathway important in inflammation, called TNF-α, was highly active. When they treated the organoids with acyclovir, the standard of care for HSV-1 encephalitis, viral replication stopped -- but the tissue damage continued. Further analysis showed the TNF-α pathway was still active despite treatment.

A defense that can become damaging

"The inflammation pathway is a key natural defense to the virus," says Dr. Tancredi Massimo Pentimalli, a medical doctor now doing his PhD in systems medicine at the Rajewsky lab and one of the first authors. "But when we block viral replication with anti-viral drugs, the overzealous inflammatory response could instead become damaging."

Rybak-Wolf treated the organoids with both an anti-viral and an anti-inflammatory drug, which would turn off the TNF-α pathway. This combined treatment prevented the damage of mini-brains. "There is a signaling pathway in the brain that becomes active during infection," she says. "When we switched it off using these drugs, the organoid wasn't damaged."

The scientists hope doctors will trial acyclovir and an anti-inflammatory as a treatment for HSV-1 encephalitis. "I hope that clinical investigators will set up clinical trials evaluating the efficacy of new anti-viral and anti-inflammatory combination therapies in herpes encephalitis patients, ultimately translating our findings from the bench to the bed side," Pentimalli says.